EA201390720A1 - Способы улучшения оксигенации ткани, подвергающейся опасности - Google Patents
Способы улучшения оксигенации ткани, подвергающейся опасностиInfo
- Publication number
- EA201390720A1 EA201390720A1 EA201390720A EA201390720A EA201390720A1 EA 201390720 A1 EA201390720 A1 EA 201390720A1 EA 201390720 A EA201390720 A EA 201390720A EA 201390720 A EA201390720 A EA 201390720A EA 201390720 A1 EA201390720 A1 EA 201390720A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- disease
- risk
- transfusions
- improving
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000000287 tissue oxygenation Effects 0.000 title 1
- 208000007502 anemia Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- -1 polyoxyethylene Polymers 0.000 abstract 2
- 208000010444 Acidosis Diseases 0.000 abstract 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 abstract 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 abstract 1
- 206010021113 Hypothermia Diseases 0.000 abstract 1
- 206010021137 Hypovolaemia Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 208000010718 Multiple Organ Failure Diseases 0.000 abstract 1
- 206010034576 Peripheral ischaemia Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010049771 Shock haemorrhagic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000007950 acidosis Effects 0.000 abstract 1
- 208000026545 acidosis disease Diseases 0.000 abstract 1
- 206010051895 acute chest syndrome Diseases 0.000 abstract 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 230000002631 hypothermal effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000006213 oxygenation reaction Methods 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 229920001451 polypropylene glycol Polymers 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Surgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41351910P | 2010-11-15 | 2010-11-15 | |
| PCT/US2011/060747 WO2012068079A1 (en) | 2010-11-15 | 2011-11-15 | Methods for enhancing oxygenation of jeopardized tissue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201390720A1 true EA201390720A1 (ru) | 2013-10-30 |
Family
ID=46084364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201390720A EA201390720A1 (ru) | 2010-11-15 | 2011-11-15 | Способы улучшения оксигенации ткани, подвергающейся опасности |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20130177524A1 (https=) |
| EP (1) | EP2640684A4 (https=) |
| JP (2) | JP5823530B2 (https=) |
| KR (2) | KR20130097795A (https=) |
| CN (1) | CN103328427A (https=) |
| AU (1) | AU2011329088B2 (https=) |
| BR (1) | BR112013011858A2 (https=) |
| CA (1) | CA2817542A1 (https=) |
| CL (1) | CL2013001382A1 (https=) |
| EA (1) | EA201390720A1 (https=) |
| IL (1) | IL226285A0 (https=) |
| MX (1) | MX2013005457A (https=) |
| NZ (1) | NZ610441A (https=) |
| PE (1) | PE20140134A1 (https=) |
| SG (1) | SG190695A1 (https=) |
| WO (1) | WO2012068079A1 (https=) |
| ZA (1) | ZA201303416B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130097795A (ko) * | 2010-11-15 | 2013-09-03 | 매스트 테라퓨틱스 인코포레이티드 | 위태로운 조직의 산소화 증강 방법 |
| GB201207543D0 (en) * | 2012-05-01 | 2012-06-13 | Haemair Ltd | Treatment of transfusion blood |
| EP3057598A1 (en) * | 2013-10-16 | 2016-08-24 | Mast Therapeutics, Inc. | Diuretic induced alterations of plasma volume |
| US9757411B2 (en) | 2014-07-07 | 2017-09-12 | Aires Pharmaceuticals, Inc. | Poloxamer therapy for heart failure |
| JP6747748B2 (ja) | 2014-07-07 | 2020-08-26 | ライフラフト バイオサイエンシーズ，インコーポレイテッド | 長期循環物質のないポロクサマー組成物、その産生方法およびその使用 |
| WO2016007542A1 (en) | 2014-07-07 | 2016-01-14 | Mast Therapeutics, Inc. | Poloxamer therapy for heart failure |
| US12310982B2 (en) | 2018-12-10 | 2025-05-27 | Elena Valentinovna ARSHINTSEVA | Use of the poloxamer as a pharmacologically active substance |
| CN118076227A (zh) * | 2021-08-18 | 2024-05-24 | 欧姆尼奥克斯股份有限公司 | 用于器官保存的h-nox蛋白 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873083A (en) | 1986-05-15 | 1989-10-10 | Emory University | Fibrinolytic composition |
| US5028599A (en) | 1986-05-15 | 1991-07-02 | Emory University | Method of treating mycardial damage |
| US4997644A (en) | 1986-05-15 | 1991-03-05 | Emory University | Method of treating adult respiratory distress syndrome |
| US5080894A (en) | 1986-05-15 | 1992-01-14 | Emory University | Method and composition for reducing tissue damage |
| US5064643A (en) | 1986-05-15 | 1991-11-12 | Emory University | Method for treating sickle cell disease |
| US4897263A (en) | 1986-05-15 | 1990-01-30 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
| US5071649A (en) | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
| US5030448A (en) | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
| US5089260A (en) | 1986-05-15 | 1992-02-18 | Emory University | Method of treating ischemic tissue |
| US5017370A (en) | 1986-05-15 | 1991-05-21 | Emory University | Improved method of performing angioplasty procedures |
| US4801452A (en) | 1986-05-15 | 1989-01-31 | Hunter Robert L | Fibrinolytic composition |
| US4879109A (en) | 1986-05-15 | 1989-11-07 | Emory University | Method for treating burns |
| US4837014A (en) | 1986-05-15 | 1989-06-06 | Emory University | An improved method of treating sickle cell anemia |
| US5041288A (en) | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
| US4937070A (en) | 1986-05-15 | 1990-06-26 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
| US5047236A (en) | 1986-05-15 | 1991-09-10 | Emory University | Method of treating stroke |
| US5078995A (en) | 1986-05-15 | 1992-01-07 | Emory University | Fibrionolytic composition |
| US5039520A (en) | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
| US5032394A (en) | 1986-05-15 | 1991-07-16 | Emory University | Method of treating burns |
| US5696298A (en) | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| ES2140408T3 (es) | 1991-03-19 | 2000-03-01 | Cytrx Corp | Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada. |
| US5605687A (en) | 1992-05-15 | 1997-02-25 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for repair of electrical injury |
| US7087369B2 (en) * | 2003-12-17 | 2006-08-08 | The Regents Of The University Of California | Cornea preservation medium |
| AU2005289520A1 (en) * | 2004-09-27 | 2006-04-06 | Vical Incorporated | Formulations and methods for treatment of inflammatory diseases |
| US20110212047A1 (en) * | 2007-08-10 | 2011-09-01 | Synth Rx, Inc. | Polymer Therapy for the Treatment of Chronic Microvascular Diseases |
| KR20130097795A (ko) * | 2010-11-15 | 2013-09-03 | 매스트 테라퓨틱스 인코포레이티드 | 위태로운 조직의 산소화 증강 방법 |
-
2011
- 2011-11-15 KR KR1020137015206A patent/KR20130097795A/ko not_active Ceased
- 2011-11-15 SG SG2013035449A patent/SG190695A1/en unknown
- 2011-11-15 MX MX2013005457A patent/MX2013005457A/es not_active Application Discontinuation
- 2011-11-15 BR BR112013011858A patent/BR112013011858A2/pt not_active IP Right Cessation
- 2011-11-15 EA EA201390720A patent/EA201390720A1/ru unknown
- 2011-11-15 NZ NZ610441A patent/NZ610441A/en unknown
- 2011-11-15 PE PE2013001082A patent/PE20140134A1/es not_active Application Discontinuation
- 2011-11-15 WO PCT/US2011/060747 patent/WO2012068079A1/en not_active Ceased
- 2011-11-15 EP EP11841387.1A patent/EP2640684A4/en not_active Withdrawn
- 2011-11-15 KR KR1020157030550A patent/KR20150124457A/ko not_active Ceased
- 2011-11-15 CN CN2011800648610A patent/CN103328427A/zh active Pending
- 2011-11-15 AU AU2011329088A patent/AU2011329088B2/en active Active
- 2011-11-15 CA CA2817542A patent/CA2817542A1/en not_active Abandoned
- 2011-11-15 JP JP2013538989A patent/JP5823530B2/ja active Active
-
2013
- 2013-03-01 US US13/783,158 patent/US20130177524A1/en not_active Abandoned
- 2013-05-09 IL IL226285A patent/IL226285A0/en unknown
- 2013-05-10 ZA ZA2013/03416A patent/ZA201303416B/en unknown
- 2013-05-15 CL CL2013001382A patent/CL2013001382A1/es unknown
-
2014
- 2014-11-25 US US14/553,913 patent/US20150093368A1/en not_active Abandoned
-
2015
- 2015-10-07 JP JP2015199281A patent/JP2016041714A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ610441A (en) | 2016-02-26 |
| CL2013001382A1 (es) | 2013-12-20 |
| EP2640684A4 (en) | 2014-04-30 |
| AU2011329088B2 (en) | 2016-02-25 |
| KR20130097795A (ko) | 2013-09-03 |
| AU2011329088A1 (en) | 2013-06-27 |
| PE20140134A1 (es) | 2014-02-14 |
| WO2012068079A1 (en) | 2012-05-24 |
| SG190695A1 (en) | 2013-07-31 |
| BR112013011858A2 (pt) | 2017-03-21 |
| JP2014506234A (ja) | 2014-03-13 |
| US20150093368A1 (en) | 2015-04-02 |
| JP2016041714A (ja) | 2016-03-31 |
| EP2640684A1 (en) | 2013-09-25 |
| CA2817542A1 (en) | 2012-05-24 |
| KR20150124457A (ko) | 2015-11-05 |
| IL226285A0 (en) | 2013-07-31 |
| US20130177524A1 (en) | 2013-07-11 |
| JP5823530B2 (ja) | 2015-11-25 |
| MX2013005457A (es) | 2013-10-17 |
| CN103328427A (zh) | 2013-09-25 |
| ZA201303416B (en) | 2017-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201390720A1 (ru) | Способы улучшения оксигенации ткани, подвергающейся опасности | |
| Bissinger et al. | Oxidative stress, eryptosis and anemia: a pivotal mechanistic nexus in systemic diseases | |
| Artigas et al. | Role of albumin in diseases associated with severe systemic inflammation: pathophysiologic and clinical evidence in sepsis and in decompensated cirrhosis | |
| Gombotz | Patient blood management: a patient-orientated approach to blood replacement with the goal of reducing anemia, blood loss and the need for blood transfusion in elective surgery | |
| Auerbach et al. | Iron: the new advances in therapy | |
| Rawal et al. | Anemia in intensive care: a review of current concepts | |
| Beer et al. | Intraoperative ventilation strategy during cardiopulmonary bypass attenuates the release of matrix metalloproteinases and improves oxygenation | |
| EA201591246A1 (ru) | Раствор для сохранения сосудистых трубок | |
| Guidry et al. | Initial assessment on the impact of crystalloids versus colloids during damage control resuscitation | |
| RU2014124171A (ru) | Лекарственное средство для терапевтического лечения и/или улучшения состояния при сепсисе | |
| EP4406595A3 (en) | Intradialytic use of sodium nitrite | |
| US20180271900A1 (en) | Reducing the proliferation of lung carcinoma cells (a549) by administration of a poly-oxygenated metal hydroxide | |
| Balci et al. | Effect of restrictive fluid management and acute normovolemic intraoperative hemodilution on transfusion requirements during living donor hepatectomy | |
| Rudis et al. | Managing anemia in the critically ill patient | |
| US20180264035A1 (en) | Reducing the proliferation of adenocarcinoma cells (caco-2) by administration of a poly-oxygenated metal hydroxide | |
| Vadehra et al. | Treating a patient with your hands tied: acute chest syndrome in a Jehovah's witness | |
| ES2761308T3 (es) | Uso de compuestos de vanadio para mantener la normoglucemia en un mamífero | |
| JP2022535801A (ja) | Ｋｌｏｔｈｏタンパク質の産生を活性化するクエン酸塩およびカルニチンを含む組成物 | |
| Lebiedz et al. | Influence of red blood cell storage time on clinical course and cytokine profile in septic shock patients | |
| Cowie et al. | Iron replacement therapy in chronic heart failure | |
| Raoof | Postoperative management of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy | |
| Hunt et al. | Inpatient management of sickle cell disease | |
| Bacuzzi et al. | Strategic and operational aspects of the Jeovah’s witness patient’s candidates for deceased-donor kidney transplant. | |
| Zhu et al. | A Comparison of Hydroxocobalamin Versus Methylene Blue in Refractory Vasodilatory Shock after Cardiopulmonary Bypass (CPB) or Extracorporeal Membrane Oxygenation (ECMO) | |
| Ho et al. | Reverse survivor bias in observational studies involving cohorts: a lesson from'1: 1'trauma studies |